Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background . Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death. Aim . Evaluate the humanistic and economic burden of CAD and PAD and identify unmet needs through a comprehensive literature review. Methods . Relevant search terms were applied across online publication databases. Studies published between January 2010 and August 2017 meeting the inclusion/exclusion criteria were selected; guidelines were also included. Two rounds of screening were applied to select studies of relevance. Results . Worldwide data showed approximately 5–8% prevalence of CAD and 10–20% prevalence of PAD, dependent on the study design, average age, gender, and geographical location. Data from the REACH registry indicated that 18–35% of patients with CAD and 46–68% of patients with PAD had disease in one or more vascular beds. Use of medication to control modifiable CV risk factors was variable by country (lower in France than in Canada); statins and aspirin were the most widely used therapies in patients with chronic disease. Survival rates have improved with medical advancements, but there is an additional need to improve the humanistic burden of disease (i.e., associated disability and quality of life). The economic burden of atherothrombotic disease is high and expected to increase with increased survival and the aging population. Conclusion . CAD and PAD represent a substantial humanistic and economic burden worldwide, highlighting a need for new interventions to reduce the incidence of atherothrombotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Baseline characteristics and medication use and clinical outcomes in patients with CAD and PAD from the REACH Registries of (a) Canada,a (b) France,b and (c) Germanyc [1, 2]. aPatients enrolled from January to October 2004; mean age 68.4 ± 9.9. bPercentage of patients experiencing at least one CV event (Figure (a): CAD n = 1356, PAD n = 146; Figure (b): CAD n = 2397, PAD n = 882; Figure (c): CAD n = 3328, PAD n = 1303). cPatients enrolled from December 2003 to June 2014; mean age 69.1–71.7 across risk groups. dPatients enrolled from December 2003 to June 2014; mean age 68.0–69.4 across risk groups. ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CAD, coronary artery disease; CV, cardiovascular; PAD, peripheral artery disease.](https://figures.cochat.ai/paper-figures/5e14fc8ebda846379e697620627d3268/burden-of-coronary-artery-disease-and-peripheral-artery-disease-a-literature-figure-1.jpg)
![Figure 2 The persistent risk of MACE (a) up to 3 years following an index MI (adapted from Blin et al., 2016) [3] and (b) up to 4.5 years following an index MI stratified by age (<72 years old versus ≥72 years old) and risk category (low versus higha) (adapted from Jernberg et al., 2015) [4]. aHigh-risk patients were predefined as those with ≥1 of the following risk factors prior to index; MI: diabetes mellitus, at least one MI prior to index MI event, CABG (proxy for multi-vessel CAD), PAD, stroke, heart failure, or diagnosis of chronic renal dysfunction. CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; HR, high risk; LR, low risk; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral artery disease.](https://figures.cochat.ai/paper-figures/ef7f32f05aeb4415a5daae684132145b/burden-of-coronary-artery-disease-and-peripheral-artery-disease-a-literature-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mere presence of PAD significantly increases the risk of having atherosclerotic disease in other vascular beds.”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Approximately, 46% to 68% of patients with PAD also had coronary artery disease (CAD) or cerebrovascular disease.[48][49][50]”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191 · cited 1×
“These conditions are characterized by progressive (CLI) or sudden onset (ALI) of pain at rest or nonhealing ischemic wounds or gangrene [27, 44, 45] and can ultimately lead to a loss of limbs [46].”
Background2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Kyu, H. H., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32335-3 · Cited by 4,081
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Hirsch, A. T., Haskal, Z. J., Hertzer, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174526 · Cited by 3,708
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,410
Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32130-x · Cited by 2,083 · cited 1×
“of mortality and morbidity worldwide, atherothrombotic disease places a substantial medical and economic burden on society [7, 12].”
Background2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease
Gerhard-Herman, M. D., Gornik, H. L., Barrett, C., Barshes, N. R., Corriere, M. A., Drachman, D. E., Fleisher, L. A., Fowkes, F. G. R., Hamburg, N. M., Kinlay, S., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.007 · Cited by 1,941
Research works printed but not linked: 1
- Gowdak L. H. W. Prevalence of refractory angina in clinical practice Heart and Metabolism 2017 72 9 12 2-s2.0-85018667587
Cited by
Items 101–200 of 482
Gioscia, R., Castagno, C., Verdoia, M., Conti, B., Forliti, E., & Rognoni, A. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i4.142 · Cited by 12
Pelletier‐Galarneau, M., Vandenbroucke, E., Lu, M., & Li, O. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03218-7 · Cited by 12
“CAD is the cause of one-third of all deaths in people aged ≥ 35, with a prevalence of 5–8% globally [2, 4].”
BackgroundJo, U., & Park, K. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.06.013 · Cited by 12
Lipid Optimization in Lower Extremity Peripheral Arterial Disease
Sucharitkul, P. P. J., Jones, K. L., Scott, D. J. A., & Bailey, M. A. (2021) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2021.03.055 · Cited by 12
Diversity in randomized clinical trials for peripheral artery disease: a systematic review
Long, C. A., Williams, A. O., McGovern, A. M., Jacobsen, C. M., Hargens, L. M., Duval, S., & Jaff, M. R. (2024) · International Journal for Equity in Health · doi:10.1186/s12939-024-02104-8 · Cited by 11
“Peripheral artery disease (PAD) is associated with serious adverse medical events and substantial health-care spending [1, 2].”
BackgroundPaskiewicz, A., Wang, F. M., Ishigami, J., Pang, Y., Sang, Y., Ballew, S. H., Grams, M. E., HEISS, G. M., Coresh, J., & Matsushita, K. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118558 · Cited by 10
Artyszuk, Ł., Błażejowska, E., Danielecka, Z., Jurek, J., Olek, E., & Abramczyk, P. (2023) · Echocardiography · doi:10.1111/echo.15652 · Cited by 10
“It is estimated that in 2016 around 120 million people were afflicted with lower extremity PAD and as much as 48% of them could have CAD or other CVD 51 .”
BackgroundDesai, R., Damarlapally, N., Bareja, S., Arote, V., Vasudevan, S. S., Mehta, K., Ashfaque, M., Jayachandran, Y., Sampath, S., Behera, A., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2401632 · Cited by 10
Tsai, T., Hsu, P., Wu, C., Huang, S., Chan, W., Lin, S., Chen, J., Lu, T., & Leu, H. (2022) · Nutrients · doi:10.3390/nu14153163 · Cited by 10
“Coronary artery disease (CAD) is a major health risk affecting millions of people worldwide [1].”
BackgroundBurden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care
Darbà, J., & Marsà, A. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2108794 · Cited by 11
“Overall, ischemic heart disease and coronary artery disease are associated to a significant burden in terms of disability and mortality, as well as significant medical costs [8].”
BackgroundQin, L., Cui, J. G., & Li, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810622 · Cited by 12
Kentenich, H., Müller, D., Wein, B., Stock, S., & Seleznova, Y. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069832 · Cited by 10
Mortality differences by race over 20 years in individuals with peripheral artery disease
Dicks, A. B., Lakhter, V., Elgendy, I. Y., Schainfeld, R. M., Mohapatra, A., Giri, J. S., Weinberg, M. D., Weinberg, I., & Parmar, G. M. (2023) · Vascular Medicine · doi:10.1177/1358863x231159947 · Cited by 10
Association between periodontal disease and coronary heart disease: A bibliometric analysis
Song, W., Bo, X.-W., Dou, H.-X., Fan, Q., & Wang, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28325 · Cited by 14
“CRP has also been shown to upregulate thrombosis, inflammation, and atherosclerosis, which are likely to lead to or aggravate CHD events [53 – 56].”
BackgroundLi, Q., Qin, L., & Li, J. (2021) · The Journal of Physiology · doi:10.1113/jp281704 · Cited by 10
“Importantly, PAD patients are at high risk of myocardial infarctions, cerebral vascular accidents and all-cause mortality (Ouriel, 2001; Anand et al. 2018; Bauersachs et al. 2019) with a death rate similar to that seen in patients with coronary or cerebral vascular disease.”
ResultAortic Thrombosis following COVID-19: A Systematic Review
Petrov, A., Romera, J. P. D. G., Wilbring, M., Alexiou, K., Kappert, U., Matschke, K. E., & Tugtekin, S. (2022) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/s-0041-1740554 · Cited by 10
Socioeconomic factors predict successful supervised exercise therapy completion
Donohue, J. K., Jarosinski, M. C., Reitz, K. M., Khamzina, Y., Ledyard, J. D., Liang, N. L., Chaer, R. A., & Sridharan, N. D. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.12.008 · Cited by 9
Lim, K. K., Koleva‐Kolarova, R., Kamaruzaman, H. F., Kamil, A. A., Chowienczyk, P., Wolfe, C. D. A., & Fox-Rushby, J. A. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030058 · Cited by 9
Bauer, J., Vlcek, J., Pauly, V., Hesse, N., Xia, R., Mo, L., Chivukula, A. S., Villgrater, H. E., Dressler, M., Hildebrand, B., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032405 · Cited by 9
Özkan, C., Dolu, A. K., Çelik, M. C., Demirtaş, B., & Karayiğit, O. (2024) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2024.4407 · Cited by 14
LT-YOLO: long-term temporal enhanced YOLO for stenosis detection on invasive coronary angiography
Li, J., Tang, X., & Wang, X. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1558495 · Cited by 10
Brain‑heart axis: Neurostimulation techniques in ischemic heart disease (Review)
Liu, Y., Yang, H., Xiong, J., Wei, Y., Chen, Y., Zheng, Q., & Liang, F. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5589 · Cited by 12
“Age and sex further influence susceptibility, with men being more prone to IHD after the age of 45 and women experiencing a heightened risk post‑menopause due to the decline in the cardioprotective effects of estrogen (12,13).”
Pelletier‐Galarneau, M., Cabra, A., Szabó, E., & Angadageri, S. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04225-y · Cited by 9
Zhang, B., Zeng, K., Li, R., Jiang, H., Gao, M., Zhang, L., Li, J., Guan, R., Liu, Y., Qiang, Y., et al. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021427 · Cited by 10
Posadas‐Sánchez, R., Vargas‐Alarcón, G., Cárdenas, A., Texcalac-Sangrador, J. L., Osorio-Yáñez, C., & Sánchez-Guerra, M. (2022) · Biology · doi:10.3390/biology11081122 · Cited by 10
“5 [52] may target key processes of atherosclerosis—the underlying pathophysiology of coronary artery disease (CAD) [54].”
Adhesion Molecules as Prognostic Biomarkers in Coronary Artery Disease
Sagris, Μ., Theofilis, P., Antonopoulos, A. S., Oikonomou, E. K., Simantiris, S., Papaioannou, S., Tsioufis, C., & Tousoulis, D. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230104125104 · Cited by 10
Kott, K. A., Genetzakis, E., Gray, M. P., Hansen, P. R., McGuire, H. M., Yang, J. Y. H., Grieve, S. M., Vernon, S. T., & Figtree, G. A. (2023) · Biomolecules · doi:10.3390/biom13081187 · Cited by 9
“There is a significant correlation between disease burden in the coronaries and other vascular beds [45,46], but further research into sLOX-1 as a CAD biomarker will need to account for atherosclerosis in these other locations.”
BackgroundTrends in Use of Cardioprotective Medication in Peripheral Artery Disease: A Nationwide Study
Kamil, S., Sehested, T. S. G., Houlind, K. C., Lassen, J. F., Gislason, G., & Domínguez, H. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020333 · Cited by 9
Leslie, W. D., Bryanton, M., Goertzen, A. L., & Slomka, P. J. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02617-7 · Cited by 9
“Coronary artery disease (CAD) remains the principle cause of death in developed countries despite major advances in both the medical and interventional approaches to management, with an emerging epidemic among low- and middle-income countries which are now responsible for overwhelming majority of cardiovascular diseas…”
Tong, J., Wang, T., Wei, Q., Hao, Q., Yu, F., Xu, X., & Zhen, P. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38034 · Cited by 8
“Cardiovascular disease (CVD) has become one of the most important public health problems in the world, and it is also one of the most important causes of death in the world, among which the prevalence and mortality of coronary heart disease (CHD) are the highest [1,2].”
Tasmurzayev, N., Baigarayeva, Z., Amangeldy, B., Иманбек, Б., Kurmanbek, S., Dikhanbayeva, G., & Amirkhanova, G. A. (2025) · Algorithms · doi:10.3390/a18110697 · Cited by 9
“Patients with IHD and concomitant heart failure have significantly higher mortality rates, underscoring the importance of early detection and prevention of disease progression [9].”
InfluentialBhalke, J., Hiremath, S., & Makhale, C. N. (2022) · Journal of interventional medicine · doi:10.1016/j.jimed.2022.09.005 · Cited by 8
Combined polygenic scores for ischemic stroke risk factors aid risk assessment of ischemic stroke
Huang, S., Joshi, A., Shi, Z., Wei, J., Tran, H. M., Zheng, S. L., Duggan, D. J., Ashworth, A., Billings, L. K., Helfand, B. T., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131990 · Cited by 8
Abdul‐Rahman, T., Roy, P., Herrera‐Calderón, R. E., Mueller-Gomez, J. L., Lisbona-Buzali, M., Ulusan, S., Awuah, W. A., Kuchma, N., Mehta, N., Agrawal, A., et al. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2462652 · Cited by 8
Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery Disease
Bojić, M., Bielesz, B. O., Cejka, D., Schernthaner, G.-H., & Höbaus, C. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1736444 · Cited by 9
Hall, R. P., Majumdar, M., Cassidy, R., Feldman, Z. M., Suarez, S. P., Goudot, G., Bellomo, T. R., Jessula, S., Kirshkaln, A., & Dua, A. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000497 · Cited by 8
The Role of BTBD7 in Normal Development and Tumor Progression
Liu, Y., Song, J., Gu, J., Xu, S., Wang, X., & Liu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231167732 · Cited by 8
“39 Mitochondrial autophagy 40,41 and DNA repair 42,43 have been found to reduce atherosclerosis 41 and thus inhibit CAD.”
BackgroundAntiplatelet drugs do not protect from platelet-leukocyte aggregation in coronary artery disease
Schulte, C., Pieper, L., Frye, M., Waldeyer, C., Neumann, F., Brunner, F. J., & Pula, G. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.04.041 · Cited by 8
Hall, R. P., Majumdar, M., Ferreira, S. P. S., Lee, I., Bellomo, T. R., Jessula, S., Kirshkaln, A., Nuzzolo, K., Zacharias, N., & Dua, A. (2023) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.08.004 · Cited by 8
Does Age Affect the Short- and Long-Term Outcomes of Coronary Bypass Grafting?
Anand, P. A., Keshavamurthy, S., Shelley, E. M., & Saha, S. P. (2021) · International Journal of Angiology · doi:10.1055/s-0041-1735221 · Cited by 8
Automatic Ultrasound Vessel Segmentation with Deep Spatiotemporal Context Learning
Jiang, B., Chen, A., Bharat, S., & Zheng, M. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-87583-1_1 · Cited by 11
“Over 120 million people worldwide are affected by peripheral vascular disease, making it one of the leading causes of morbidity and mortality globally [1].”
BackgroundLi, Q., Qin, L., & Li, J. (2023) · Physiological Reports · doi:10.14814/phy2.15654 · Cited by 8
Ribieras, A. J., Ortiz, Y. Y., Li, Y., Le, N., Huerta, C. T., Voza, F. A., Shao, H., Vázquez-Padrón, R. I., Liu, Z., & Velazquez, O. C. (2023) · Cardiovascular Therapeutics · doi:10.1155/2023/6679390 · Cited by 8
Obino, G., Sensini, A., ten Brink, T., Nieddu, G., Bodet, T., Deiana, G. A., van Griensven, M., Formato, M., Lepedda, A. J., & Moroni, L. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505314 · Cited by 7
Guo, N., Zhou, H., Zhang, Q., Fu, Y., Jia, Q., Gan, X., Wang, Y., He, S., Li, C., Tao, Z., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03711-7 · Cited by 7
“Coronary artery disease (CAD) still poses a great threat to human health and quality of lives, although the current treatment strategies for CAD are quite mature [1, 2].”
BackgroundHigh Mobility Group Box 1 and Cardiovascular Diseases: Study of Act and Connect
Wasim, R., Singh, A., Islam, A., Mohammed, S., Anwar, A., & Mahmood, T. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09919-5 · Cited by 7
Jeong, J., Chao, C., Arsanjani, R., Ayoub, C., Lester, S. J., Pereyra, M., Said, E. F., Roarke, M. C., Tagle‐Cornell, C., Koepke, L. M., et al. (2025) · Mayo Clinic Proceedings Digital Health · doi:10.1016/j.mcpdig.2025.100300 · Cited by 8
The Importance of the Plasma Membrane in Atherogenesis
Kotlyarov, S. N., & Котлярова, А. А. (2022) · Membranes · doi:10.3390/membranes12111036 · Cited by 7
“Coronary heart disease, ischemic stroke and peripheral artery disease occupy an important place in the structure of population morbidity and carry a heavy economic and social burden [2,3].”
BackgroundHelmer, M., Scheurig‐Muenkler, C., Brandt, V., Tesche, C., Bette, S. J., Schwarz, F., Kroencke, T. J., & Decker, J. A. (2023) · Diagnostics · doi:10.3390/diagnostics13061163 · Cited by 7
“As pointed out later, PAD and CAD require similar, not equal, treatment approaches; 222 thus, it is important to ensure that patients receive the most appropriate care based on 223 their individual needs and conditions [13,14].”
InfluentialRamamoorthy, L., George, N., Satheesh, S., & Jayapragasam, K. (2021) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_443_20 · Cited by 7
“This epidemiological alteration is mainly due to the increase in the prevalence of CVDs and CVD risk factors.[1] Coronary artery disease (CAD) is of significant human cost and financial burden worldwide.”
Palma, C., David, C., Fernandes, R. M., Pinto, F. J., Costa, J. N., Ferreira, J. J., & Caldeira, D. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02658-x · Cited by 7
“A recent review of studies published between 2010 and 2017 estimated the worldwide prevalence of CAD to be approximately 5–8% [2].”
BackgroundRafiq, M., Liaquat, A., Javed, A., Shah, S. U., Hussain, R., Akram, Z., & Khan, M. J. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117416 · Cited by 7
Kamil, S., Sehested, T. S. G., Houlind, K. C., Lassen, J. F., Gislason, G., & Domínguez, H. (2022) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcac022 · Cited by 6
Church, L. A., Robins, L., Xu, F., Qin, L., Tran, A. D., Wallace, J. P., & King, S. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1389853 · Cited by 6
“In the heart these pathogens have been shown to invade vessel walls and adhere to atherosclerotic lesions, leading to atherosclerosis (19); the primary cause of CVD (20).”
BackgroundLi, Y., Zhong, W., Huang, C., Peng, J., & Li, H. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04021-8 · Cited by 6
“CAD is a serious cardiovascular disease with high morbidity and mortality, and is one of the serious disease burdens [5, 6].”
BackgroundSu, X., Zhang, M., Yang, G., Cui, X., Yuan, X., Du, L., & Pei, Y. (2024) · Medicine · doi:10.1097/md.0000000000038744 · Cited by 6
“[24] Therefore, prospecting for biomarkers of AS coupled with predicting drug efficacies are imperative to effective management of AS.”
BackgroundZhang, A., Liu, X., Li, X., Duan, N., & Huang, B. (2025) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.11610 · Cited by 6
Córdoba‐Melo, B. D., Seni-Molina, S., Arango-Ibañez, J. P., Ayala, M. R., Méndez, J., Quintero-Yepes, V., Mejía-Cadavid, L. A., Cruz-Cuevas, J. D., Ordoñez, N. A., Buitrago, A. F., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02657-9 · Cited by 6
Rahimian, A., Etehadtavakol, M., Moslehi, M., & Ng, E. Y. K. (2023) · Diagnostics · doi:10.3390/diagnostics13040611 · Cited by 6
“9 million deaths are caused each year by the cardiovascular diseases, including coronary artery diseases (CAD) such as angina and myocardial infarction [1].”
BackgroundUCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities
Staubach, P., Bilo, B., Fluhr, J. W., Krause, K., Kulthanan, K., Salman, A., Katelaris, C. H., Bernstein, J. A., Maurer, M., & Mann, C. G. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2329784 · Cited by 7
“The prevalence of CAD in our patient group is lower compared to the worldwide average of 5–8% (26).”
Genetic variants of ANRIL and coronary artery disease: Insights from a Turkish study population
Ozuynuk, A. S., Kirsan, C. B., Erkan, A. F., Ekici, B., Kömürcü-Bayrak, E., & Çoban, N. (2024) · Gene · doi:10.1016/j.gene.2024.148475 · Cited by 6
Occupational Risk for Coronary Artery Disease in Shift Workers – A Systematic Review
d’Ettorre, G., Piscitelli, P., Pellicani, V., Tornese, R., Ceccarelli, G., d’Ettorre, G., & Torre, G. L. (2024) · La Medicina del Lavoro · doi:10.23749/mdl.v115i2.15532 · Cited by 9
“To date, CAD persists as a major cause of mortality, responsible for one-third of all deaths in individuals aged ≥ 35, with a global prevalence ranging from 5% to 8% [3, 4].”
BackgroundZhong, Q., Jin, S., Zhang, Z., Qian, H., Xie, Y., Yan, P., He, W., & Zhang, L. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-03972-2 · Cited by 6
“As a multifactorial disease with high morbidity and mortality, CAD imposes a substantial burden on social economies [18].”
BackgroundZan, J., Dong, X., Yang, H., Yan, J., He, Z., Tian, J., & Zhang, Y. (2024) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s472398 · Cited by 6
Eerik, K., Kasepalu, T., Post, H., Eha, J., Kals, M., & Kals, J. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2024.10.047 · Cited by 7
Galangin reduces vascular endothelial cell dysfunction via Heme oxygenase-1 signaling
Qian, Z., & Suo, R. (2022) · Vascular · doi:10.1177/17085381221084806 · Cited by 6
Liu, S., Yin, B., Wu, B., & Fan, Z. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11333 · Cited by 6
“Acute myocardial infarction (AMI) is a major cause of disability and mortality worldwide (1).”
BackgroundKANK4 Promotes Arteriogenesis by Potentiating VEGFR2 Signaling in a TALIN-1–Dependent Manner
Zhang, C., He, H., Dai, J., Li, Y., He, J., Yang, W., Dai, J., Han, F., Kong, W., Wang, X., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317711 · Cited by 6
“Therefore, in addition to full-length KANK4, we constructed 4 different truncations: (1) lacking the N-terminal KN domain (ΔK), (2) lacking the C-terminal Ankyrin-repeats (ΔA), (3) only containing the N-terminal KN domain (KN), or (4) only containing C-terminal Ankyrinrepeats (ANK; Figure 6D).”
Javan‐Noughabi, J., Rezapour, A., Hajahmadi, M., & Alipour, V. (2022) · Scientific Reports · doi:10.1038/s41598-022-19496-8 · Cited by 6
The national moroccan registry of ST-elevation myocardial infarction (MR-MI)
Soufiani, A., Chraibi, H., Asfalou, I., Ouafi, N. E., Hattaoui, M. E., Habbal, R., Chaib, A., Fellat, R., Akoudad, H., Benyass, A., et al. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03458-7 · Cited by 6
A Practical Guide to Understanding and Treating Peripheral Artery Disease
Chilbert, M. R., Woodruff, A. E., & Rogers, K. C. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001556 · Cited by 6
Coronary Artery Calcium Score: Assessment of SYNTAX Score and Prediction of Coronary Artery Disease
Shabbir, A., Virk, S. T., Malik, J., Kausar, S., Nazir, T. B., & Javed, A. (2021) · Cureus · doi:10.7759/cureus.12704 · Cited by 6
“Introduction Coronary artery disease (CAD) is one of the major causes of morbidity and mortality worldwide, and the people of the subcontinent are more susceptible to this disease [1-3].”
BackgroundRole of serum cytokines in the prediction of heart failure in patients with coronary artery disease
Hou, Q., Sun, Z., Zhao, L., Liu, Y., Zhang, J., Huang, J., Luo, Y., Xiao, Y., Hu, Z., & Shen, A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14491 · Cited by 5
“Coronary artery disease (CAD), also called coronary heart disease, is a primary cause of HF.(5) Recent evidence has shown that 52% of patients with HF in the general population are <75 years.”
BackgroundJuan, S., Harxhi, A., Kaul, S., Woods, B., Tran, M., Geonnotti, G., Gupta, A. K., Dean, E., Saunders, C. E., & Payne, G. (2025) · JMIR Cardio · doi:10.2196/56053 · Cited by 5
“More than 18 million adults in the United States have coronary artery disease (CAD) [3], and up to 42% of these people also have peripheral artery disease (PAD) [4,5].”
First in man: a novel 355 nm laser plaque ablation system for peripheral artery disease
Wang, H., Guo, L., Zhang, Y., Zhu, R., & Guo, J. (2025) · Lasers in Medical Science · doi:10.1007/s10103-025-04490-z · Cited by 5
Pourtorabi, S. M., Kaeidi, A., & Hassanshahi, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177936 · Cited by 5
Royse, A. G., Ren, J., Bowyer, A., Reid, C. M., Bellomo, R., Smith, J. A., Bannon, P. G., Eccleston, D. S., Vallely, M. P., LUI, E. H., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.06.1018 · Cited by 5
Wu, X., Shi, J., & Liu, Q. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05054-3 · Cited by 5
“This condition affects > 230 million adults globally [2], with severe economic implica-tions—annual U.S. healthcare costs exceed $21 billion, while patients suffer 2.5-fold higher cardiovascular mortality than non-PAD counterparts [3, 4].”
InfluentialDabic, P., Petrović, J., Vučurević, B., Bucic, A., Bajčetić, D., Ilijevski, N. S., & Ševković, M. (2023) · Angiology · doi:10.1177/00033197231204087 · Cited by 5
“35-39 In the Reduction of Atherothrombosis for Continued Health (REACH) registry, 15.6% of patients enrolled in Canada, 18.2% in France, and 27.4% in Germany had established athero-thrombotic disease in more than one vascular bed (18 – 35% of patients with CAD also had PAD and/or cerebrovascular…”
Influentialde Kermenguy, C., Durand, A., Tollenaere, Q., Pabic, E. L., Paillard, F., & Mahé, G. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04289-w · Cited by 5
“LEAD, whether symptomatic or asymptomatic, is associated with an increased risk of cardiovascular (CV) mortality and morbidity, including an increased risk of developing major adverse cardio-vascular events (MACE) and major adverse limb events (MALE) [3].”
BackgroundResultInfluentialWang, Y., Lai, J., Chen, Z., Liqiang, S., Ma, Y., & Wu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1475975 · Cited by 6
“MiR-532 – 3p plays a regulatory role in metabolic disorders like in fl ammation and obesity, and contributes to atherosclerotic thrombosis, which can lead to HF(Bauersachs et al., 2019; Huang et al., 2020).”
Akhtar, M., Ashraf, D. A., Nadeem, M. S., Maryam, A., Ahmed, H., Akhtar, M., Picker, S. M., & Ahmed, R. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200374 · Cited by 5
“This progressive disorder is characterized by endothelial damage, low-grade inflammation, lipid accumulation, and plaque formation within the intima of the blood vessel wall [3].”
Hosseinkhani, S., Emamgholipour, S., Salari, P., Khalagi, K., Shirani, S., Najjar, N., Larijani, B. A., Pasalar, P., & Razi, F. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002016 · Cited by 5
Laivuori, M., Biancari, F., Sinisalo, J. P., Albäck, A., Hakovirta, H. H., Sund, R., & Venermo, M. A. (2022) · VASA · doi:10.1024/0301-1526/a001041 · Cited by 5
Alzarroug, A. F., Gahtani, H. K. A., Algahtani, S., Alghamdi, H. K., Alhinti, M. F., Almutairi, K. A., & Algahtani, S. (2023) · Cureus · doi:10.7759/cureus.35514 · Cited by 5
“Studies attribute CAD to about two percent of the global disease burden [1].”
BackgroundKhan, M. S., Anker, S. D., Filippatos, G. S., Ferreira, J. P., Pocock, S., Januzzi, J. L., Chopra, V., Piña, I. L., Böhm, M., Ponikowski, P. P., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.06.024 · Cited by 5
Enciu, A., Löschner, D., Alhallak, M., Kellner, G., Meyer, A., Lauten, A., Steinbrecher, A., & Gerlach, R. (2023) · Acta Neurochirurgica · doi:10.1007/s00701-023-05766-5 · Cited by 5
“However, coronary artery, cerebrovascular, and peripheral artery disease can also lead to perioperative lifethreatening events, such as myocardial infarction, stroke, limb ischemia, and heart failure [1].”
BackgroundAboyans, V., Morbœuf, O., Grenier, B., Jolivel, R., & Bura-Rivière, A. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2024.01.091 · Cited by 5
Yılmaz, A. Ş., Kahraman, F., Ersoy, İ., Taylan, G., Kaya, E. E., Aydın, E., Karakayalı, M., Öğütveren, M. M., Taşdelen, A. G., Kümet, Ö., et al. (2024) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2023.67505 · Cited by 5
“21 It can be suggested that patients may be screened for PAD presence, even if they have no chief complaints related to it.”
BackgroundEffects of acute and chronic stair-climbing exercise on metabolic health: A systematic review
Hong, J.-Y., Li, Y.-J., Metcalfe, R. S., & Chen, Y.-C. (2024) · Journal of Sports Sciences · doi:10.1080/02640414.2024.2345414 · Cited by 5
“The prevalence and burden of both type 2 diabetes and cardiovascular disease remains extremely high worldwide (Bauersachs et al., 2019; Standl et al., 2019).”
BackgroundKhan, M. S. N., Khan, M. I., Saqlain, A., Umer, S., Haider, M., & Ashiq, K. (2024) · Cureus · doi:10.7759/cureus.64670 · Cited by 5
“Cardiovascular diseases (CVDs) are a major source of morbidity and death, with coronary artery disease (CAD) being one of the main causes [1,2].”
BackgroundStanytė, A., Fineberg, N. A., Gečaitė-Stončienė, J., Podlipskytė, A., Neverauskas, J., Juškienė, A., Steiblienė, V., Kažukauskienė, N., & Burkauskas, J. (2024) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2024.152570 · Cited by 6
“CAD leads to a poorer health-related quality of life and related disability [3].”
Ezekwueme, F., Tolu-Akinnawo, O. Z., Smith, Z., & Ogunniyi, K. E. (2025) · Cureus · doi:10.7759/cureus.78994 · Cited by 10
Review of the use of simulators in learning revascularization techniques
EL‐Andari, R., Bozso, S. J., Kang, J. J. H., & Nagendran, J. (2021) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-020-01577-y · Cited by 5
“Various medical treatments are available to treat the symptoms of CAD [1–3] although revascularization using percutaneous coronary intervention (PCI) or CABG (coronary artery bypass grafting) is currently indicated for patients who have CAD inadequately managed with maximal medical therapy, or those that are at high r…”
BackgroundMethodTeo, Y. N., Teo, Y. H., Syn, N. L. X., Goh, M. W., Yoong, C. S. Y., Lee, C., Chan, M. Y., Chai, P., Yeo, T., & Sia, C. (2021) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00460-y · Cited by 5
“Coronary artery disease contributes a significant global burden of cardiovascular disease, prompting heavy interest in pharmacological therapies to reduce its long-term sequalae [1, 2].”
BackgroundMetabolic Syndrome and Risk of Peripheral Arterial Disease: A Systematic Review and Meta-Analysis
Soriano‐Moreno, D. R., Fernandez-Morales, J., Medina-Ramírez, S. A., Coico-Lama, A. H., Soriano-Moreno, A. N., & Zafra‐Tanaka, J. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000470 · Cited by 5
Ma, L., Li, L., Ma, F., Ma, F., & Ma, S. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001244 · Cited by 5
Lee, K., Chung, K., Chen, H., Cheng, K., Wu, K., & Song, L. (2023) · Cancer Causes & Control · doi:10.1007/s10552-023-01803-x · Cited by 5
“Aspirin is then widely applied in certain cardio-vascular diseases, including ischemic heart disease (IHD) and cerebrovascular infarction (CVI) [17–19].”
Michael, A. E., Schoenbeck, D., Becker-Assmann, J., Haag, N. P., Niehoff, J. H., Schmidt, B. T., Panknin, C., Baer‐Beck, M., Hickethier, T., Maintz, D. C., et al. (2023) · BJR|Open · doi:10.1093/bjro/tzae030 · Cited by 4
Demirkıran, T., Akyol, F. B., Özdem, T., Hacızade, E., Kubat, E., Erol, G., Kadan, M., & Karabacak, K. (2024) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2024.26471 · Cited by 4
“[24] In a retrospective study, the rate of traumatic injury to the femoral artery was 0.07% with femoral cannulation during minimally invasive cardiac surgery.”
Influential
Metadata
- Authors
- Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Klinikum Ludwigshafen (DE)
- Bayer (Germany) (DE)
- Creativ-Ceutical (France) (FR)
- Bayer (United Kingdom) (GB)
- Corresponding author
- Bauersachs, Rupert
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2019-11-26
- Volume
- 2019
- Pages
- 1-9
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- PMC
- PMC7024142
- OpenAlex
- W2990657953
- Semantic Scholar
- 7306e92becdce616c64c569876ca723660f04cb3
- Cited by
- 449
- References
- 52
- Citations by year
- 2026: 39 · 2025: 80 · 2024: 118 · 2023: 102 · 2022: 64 · 2021: 38 · 2020: 8
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Therapeutics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
- Funders
- Bayer AG
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Epidemiology › Healthcare Systems and Public Health
- Keywords
- coronary artery disease, peripheral arterial disease, atherothrombosis, disease burden, economic burden, humanistic burden, prevalence, quality of life, disability, statins, aspirin, cardiovascular risk management, survival rate, population aging, unmet needs
- MeSH terms
- Aged, Coronary Artery Disease, Female, Health Services Needs and Demand, Humans, Male, Prognosis, Risk Factors, Global Health, Incidence, Prevalence, Health Care Costs, Cost of Illness, Peripheral Arterial Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.